Startup · $750k raised
First-in-class drug ATH01 designed to clear arterial plaque directly
Programs: MTPConnect (Targeted Translation Research Accelerator (TTRA) Drugs and Devices program)
Every investor coverage indicates participated in a round Atherid Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| State Government | Accelerator | - |
| MTPConnect | Accelerator · Grant | - |
Companies Atherid Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Atherid Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Western Australia's government has shortlisted 23 companies for the 2026 Innovators of the Year awards across six categories; $310,000 in prizes will be shared in November, and past winners including Kanopy are recalled.
MTPConnect's government-backed accelerator program has awarded $12.07 million in non-dilutive grants to 14 Australian drug and device companies, which will also receive mentoring and support from partners including CSL and Roche Diagnostics.